A61K 9/1271
Non-conventional liposomes
Official title: Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers (liposomes as conjugates {A61K47/6911})
A61K9/1271 (Non-conventional liposomes) appears on 3,006 US grants and 4,835 published applications in this corpus.
Search patents in A61K- Granted patents
- 3,006
- Published applications
- 4,835
- Assignees
- 1,788
- Inventors
- 8,648
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1979 | 1 | 0 |
| 1980 | 7 | 0 |
| 1981 | 3 | 0 |
| 1982 | 6 | 0 |
| 1983 | 5 | 0 |
| 1984 | 5 | 0 |
| 1985 | 8 | 0 |
| 1986 | 8 | 0 |
| 1987 | 11 | 0 |
| 1988 | 18 | 0 |
| 1989 | 27 | 0 |
| 1990 | 24 | 0 |
| 1991 | 34 | 0 |
| 1992 | 30 | 0 |
| 1993 | 35 | 0 |
| 1994 | 31 | 0 |
| 1995 | 32 | 0 |
| 1996 | 38 | 0 |
| 1997 | 65 | 0 |
| 1998 | 102 | 0 |
| 1999 | 76 | 0 |
| 2000 | 78 | 0 |
| 2001 | 73 | 22 |
| 2002 | 71 | 87 |
| 2003 | 52 | 121 |
| 2004 | 44 | 96 |
| 2005 | 25 | 110 |
| 2006 | 38 | 102 |
| 2007 | 41 | 96 |
| 2008 | 31 | 107 |
| 2009 | 26 | 118 |
| 2010 | 49 | 128 |
| 2011 | 43 | 142 |
| 2012 | 51 | 132 |
| 2013 | 54 | 185 |
| 2014 | 91 | 203 |
| 2015 | 110 | 186 |
| 2016 | 130 | 205 |
| 2017 | 150 | 202 |
| 2018 | 136 | 222 |
| 2019 | 148 | 249 |
| 2020 | 146 | 234 |
| 2021 | 122 | 264 |
| 2022 | 139 | 313 |
| 2023 | 125 | 299 |
| 2024 | 155 | 352 |
| 2025 | 175 | 374 |
| 2026 | 137 | 286 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Methods of preparation of pan TLR antagonistic liposomal-LNP formulations and uses thereof6 Oct 2026US 12,751,920 B2Celestial Therapeutics, Inc.
- Medication that protects the intestinal microbiota and their preparation methods and applications6 Oct 2026US 12,751,921 B2University of Science and Technology of China
- Mutant influenza B/Victoria lineage virus hemagglutinin proteins6 Oct 2026US 12,752,001 B2ModernaTX, Inc.
- Oxazolidinone compounds, liposome compositions comprising oxazolidinone compounds and method of use thereof6 Oct 2026US 12,753,170 B2Akagera Medicines, Inc.
- Double-stranded RNAi agents for targeting and regulating HBV gene expression, and a use thereof6 Oct 2026US 12,753,409 B2Hangzhou Tianlong Pharmaceutical Co., Ltd.
- Modified liposome for drug delivery, use of liposome for drug delivery, especially with anti-cancer activity, and ways to load liposome with drugs, especially with anti-cancer activity8 Oct 2026US 2026/0306403 A1Bs Biotechna Spolka Akcyjna
- Liposome compositions and medical uses thereof8 Oct 2026US 2026/0306404 A1
- Leveraging lipid-protein interactions to engineer spatial organization in cell-free systems8 Oct 2026US 2026/0306405 A1
- Steroid-cationic lipid compound and use thereof8 Oct 2026US 2026/0306406 A1Cansino (Shanghai) Biological Research Co., Ltd.
- Tretinoin liposome formulations and uses thereof to treat cancer8 Oct 2026US 2026/0306436 A1Highfield Biopharmaceuticals Corporation
Most cited
By later US patents
- Delivery of exogenous DNA sequences in a mammal1,218US 5,580,859 AVical Incorporated · 1996
- Liposomes with enhanced circulation time1,198US 5,013,556 ALiposome Technology, Inc. · 1991
- Induction of a protective immune response in a mammal by injecting a DNA sequence885US 5,589,466 AVical Incorporated · 1996
- Liposomes containing modified cholesterol for organ targeting853US 4,544,545 ATrustees of the University of Massachusetts · 1985
- Liposomes with enhanced circulation time753US 4,837,028 ALiposome Technology, Inc. · 1989